 |
answer text |
<p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United
Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s
routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro
and Priorix have been evaluated before they were given a Marketing Authorisation in
Europe, and the Marketing Authorisation Holder for each vaccines is legally required
to submit periodic safety update reports to the regulator, which are documents intended
to provide an evaluation of the risk-benefit balance of a medicinal product at defined
time points after its authorisation. The sites at which the products are manufactured
are also required to undergo periodic inspections to ensure that they comply with
Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines
control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s
testing. These procedures ensure that the MMR vaccines available in the UK are safe
and efficacious and that the manufacturers/Marketing Authorisation holders are held
accountable for their products.</p><p>A European Public Assessment Report (EPAR) for
M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf"
target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix
was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro
contains a general summary of the manufacturing information that was provided during
the assessment process; however, the specific details of the manufacturing process
are confidential.</p>
|
|
